CONDITION
Hyperlipidaemia
Hyperlipidaemia describes a persistent elevation of fats—chiefly triglycerides and cholesterol—in the bloodstream. In dogs and cats, this can occur as a secondary response to other conditions such as endocrine disease or pancreatitis, or in some cases as a primary inherited tendency. It may be discovered incidentally on routine blood testing, or it may be accompanied by visible changes such as cloudiness in the eyes, skin lesions, or gastrointestinal signs. Many animals with hyperlipidaemia show no outward signs at all, particularly in the early stages. When signs do appear, they vary widely depending on the underlying cause and the degree of lipid elevation. Some owners notice their pet seems quieter after meals, or that blood drawn for testing appears milky or opaque. This page explores the observable signals that may accompany hyperlipidaemia, the metabolic processes that lead to lipid accumulation, the investigations used to characterise the pattern and identify contributing factors, and the range of dietary and medical approaches that may be considered in managing the condition.
Why this matters now
Hyperlipidaemia can appear at any age, though primary inherited forms tend to emerge in young to middle-aged animals, often in specific breeds such as Miniature Schnauzers and Shetland Sheepdogs. Secondary hyperlipidaemia is more commonly observed in middle-aged to older dogs and cats, where it arises in response to conditions such as hypothyroidism, diabetes mellitus, hyperadrenocorticism, or pancreatitis. Dietary factors—particularly high-fat meals or prolonged fasting—can also influence lipid levels, and some animals show transient elevations after eating that resolve within hours.
The course of hyperlipidaemia varies considerably depending on whether it is primary or secondary, and on the degree of lipid elevation. Some animals remain entirely asymptomatic for years, with the condition detected only incidentally during routine blood work. In others, lipid accumulation may progress to visible or systemic changes, particularly when triglyceride levels remain persistently high or when an underlying endocrine disorder remains unmanaged. The rate of progression is highly individual and often reflects the natural history of any concurrent disease.
Signals & patterns
Early signals
Milky or cloudy blood samples
Some owners notice that blood drawn during routine testing appears opaque, pale, or milky rather than the typical deep red. This reflects the presence of very high levels of triglycerides suspended in the plasma, a finding often described as lipaemia.
Cloudy appearance in the eyes
A hazy or bluish-white cloudiness may develop in one or both eyes, particularly in the front chamber or throughout the cornea. This occurs when lipid particles accumulate in ocular tissues and can appear quite striking, though it does not always affect vision in the early stages.
Intermittent gastrointestinal upset
Some animals experience episodes of vomiting, loose stools, or reduced appetite, particularly after meals. These signs can be mild and sporadic, and may be mistaken for dietary indiscretion or sensitivity.
Quiet behaviour after eating
An owner may observe that their pet seems less active or more subdued following meals, or appears less interested in food than usual. This pattern can be subtle and is easily overlooked.
Later signals
Skin nodules or swellings
Firm, raised bumps or yellowish plaques may appear on the skin, particularly around pressure points, the limbs, or the trunk. These lesions, known as xanthomas, represent collections of lipid-laden immune cells and can vary in size and number.
Recurrent abdominal pain
Some animals develop recurring episodes of abdominal discomfort, restlessness, or a hunched posture. This pattern may reflect inflammation of the pancreas or other abdominal structures in response to sustained lipid elevation.
Neurological changes
In rare cases, particularly in cats or dogs with very severe hypertriglyceridaemia, signs such as disorientation, head tilt, circling, or seizures may emerge. These reflect lipid deposition or vascular disturbances affecting the nervous system.
Click to read about the biological mechanisms
How this is usually investigated
Investigation typically begins with a detailed history, including recent meals, fasting duration, and any medications or supplements, since these can all influence lipid levels. A physical examination may reveal visible signs such as corneal opacity or skin nodules, though many animals show no outward changes. Blood testing forms the foundation of the investigation, with additional tests selected to identify or exclude underlying conditions that commonly drive lipid elevation.
Fasted blood biochemistry and triglyceride measurement
Endocrine function tests
Pancreatic enzyme measurement
Urinalysis and urine protein measurement
Abdominal ultrasonography
Options & trade-offs
Management of hyperlipidaemia is typically individualised, combining dietary modification, treatment of any underlying conditions, and in some cases medication to reduce circulating lipids. The approach varies depending on whether the hyperlipidaemia is primary or secondary, the degree of lipid elevation, and the presence of clinical signs. Different combinations suit different households, and what proves workable for one animal may be less practical for another.
Dietary fat restriction
Reducing dietary fat intake can lower triglyceride levels by decreasing the intestinal absorption and hepatic processing of lipids. This often involves switching to a commercial low-fat diet or preparing meals with lean protein sources and minimal added fats. The degree of restriction varies; some animals require very strict limitation, while others respond to moderate reduction.
Trade-offs: Palatability can be an issue for some animals, and adherence may be difficult in multi-pet households or where treats and table foods form part of the routine. Fat restriction alone may not normalise lipid levels in animals with primary hyperlipidaemia or significant endocrine disease.
Treatment of underlying endocrine or metabolic disease
When hyperlipidaemia arises secondary to conditions such as hypothyroidism, diabetes mellitus, or hyperadrenocorticism, managing the primary disorder often leads to improvement in lipid levels. This may involve thyroid hormone supplementation, insulin therapy, or medical or surgical management of adrenal disease. The timeline for lipid normalisation varies, and some animals show partial rather than complete resolution.
Trade-offs: Response depends on the severity and duration of the underlying condition, and lipid levels may remain mildly elevated even with good disease control. Monitoring both the primary disorder and lipid levels requires ongoing blood testing.
Omega-3 fatty acid supplementation
Supplementation with marine-derived omega-3 fatty acids, particularly eicosapentaenoic acid and docosahexaenoic acid, can reduce triglyceride synthesis and enhance lipid clearance in some animals. The dose and formulation vary, and response is often partial rather than complete. Omega-3 supplementation is sometimes combined with dietary fat restriction.
Trade-offs: Not all animals show a measurable response, and high doses may cause gastrointestinal upset or a fishy odour to the breath or coat. The evidence base is stronger for triglyceride reduction than for cholesterol lowering.
Lipid-lowering medication
Drugs such as fibrates or niacin derivatives can reduce circulating triglycerides by enhancing lipoprotein lipase activity or altering hepatic lipid metabolism. These are typically reserved for animals with persistent, marked hyperlipidaemia that has not responded to dietary modification and treatment of underlying disease, or for those showing clinical signs such as recurrent pancreatitis or lipid deposits in tissues.
Trade-offs: Medication requires regular monitoring for side effects, including gastrointestinal disturbance and liver enzyme elevation. Response is variable, and some animals achieve only partial lipid reduction despite treatment.
Serial monitoring without active intervention
In animals with mild, asymptomatic hyperlipidaemia and no identified underlying disease, periodic blood testing without immediate dietary or medical intervention may be considered. This approach allows observation of the natural course and identification of any progression or resolution over time. It is most often considered in cases of isolated mild cholesterol elevation.
Trade-offs: Monitoring alone does not address the lipid elevation, and there remains some uncertainty about long-term risks such as pancreatitis or vascular changes. It may be less suitable for animals with marked triglyceride elevation or those in breeds predisposed to primary hyperlipidaemia.
Common misconceptions
"A high-fat diet always causes hyperlipidaemia."
Dietary fat can contribute to lipid elevation, particularly in animals with an underlying predisposition, but many dogs and cats tolerate high-fat diets without developing hyperlipidaemia. The response to dietary fat varies widely between individuals, and some animals show persistent lipid elevation even on very low-fat diets, reflecting inherited or secondary metabolic factors rather than diet alone.
"Hyperlipidaemia is always a sign of serious disease."
While hyperlipidaemia can accompany conditions such as diabetes or hypothyroidism, many animals have mild lipid elevations that reflect benign inherited tendencies or transient dietary effects. The clinical significance depends on the degree of elevation, the presence of symptoms, and whether an underlying disorder can be identified. Some animals live normally with mild hyperlipidaemia that requires no intervention.
"Once lipid levels normalise, dietary restriction can be relaxed."
In animals with primary hyperlipidaemia or persistent secondary causes, lipid levels often rise again if dietary fat restriction is eased. The underlying metabolic tendency typically persists, and long-term management often involves sustained dietary modification rather than a temporary measure. The degree of restriction needed to maintain normal lipids varies between individuals and may require periodic adjustment.
Related conditions
Acute Pancreatitis
Acute pancreatitis can trigger a sudden rise in blood triglycerides, and in some cases hyperlipidaemia itself may contribute to inflammation of the pancreas, creating a pattern in which each condition can influence the other.
Hepatic Lipidosis
Hepatic lipidosis describes fat accumulation within liver cells, a process that can occur alongside or as a consequence of severe hyperlipidaemia, particularly in cats. Both conditions reflect disturbances in how the body processes and stores lipids.
Hypothyroidism in Cats
Hypothyroidism can slow metabolic processes that normally clear fats from the bloodstream, and when thyroid hormone levels are low, lipid levels may rise as a secondary consequence.
Nephrotic Syndrome
Nephrotic syndrome involves heavy protein loss through the kidneys, which often triggers the liver to increase production of lipoproteins, leading to secondary hyperlipidaemia as part of the body's compensatory response.
Protein-Losing Enteropathy
Protein-losing enteropathy can disrupt the normal balance of proteins in the blood, and in some cases this prompts the liver to synthesise more lipoproteins, resulting in elevated lipid levels as a secondary metabolic adjustment.
Hyperlipidaemia often exists in the context of broader metabolic or endocrine patterns, and understanding conditions such as diabetes mellitus, hypothyroidism, or pancreatitis may deepen the picture. The Metabolic Health pillar explores the interplay between these systems and how they influence one another. For animals with persistent lipid elevation despite intervention, or those showing new signs such as abdominal discomfort or visual changes, a conversation about the trajectory and the role of further testing can be a useful part of the next appointment.